Etoposide

製品コードS1225 別名:VP-16, VP-16213

Etoposide化学構造

分子量(MW):588.56

Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.

サイズ 価格(税別)  
JPY 15106.00
JPY 11620.00
JPY 46480.00

カスタマーフィードバック(6)

  • ABT-199 synergizes strongly with lymphoma chemotherapy agents that affect MCL1 levels. Viability and CI vs Fa after 24-h exposure to etoposide alone or in combination with ABT-199 in Riva, U2932 and VavP-Bcl2/c-MYC murine tumor cells. Viability shown at 500 nM.

    Leukemia, 2015, 29: 1702–1712. Etoposide purchased from Selleck.

    Dox promotes formation of DNA DSBs in primary neurons. (A) Cortical neurons at 28–32 DIV were treated with a vehicle or with Dox (0.1 μ M) or with DNA damaging drug etoposide (5 μ M) overnight, fixed, and stained for a marker of DSBs phosphorylated histone H2A variant X, γ H2A.X (green), MAP2c (red), and with the nuclear Hoechst dye (blue), and imaged. The neuronal nucleus is enlarged on the Dox panel to illustrate the γ H2A.X puncta. Note the green nuclear staining in cells treated with Dox and etoposide. Also note the reduced dendritic arborization in neurons treated with Dox and etoposide. Scale bar is 20 μm.

    Sci Rep, 2016, 6:25705.. Etoposide purchased from Selleck.

  • Viability of U87 cells(C) assessed by the Alamar blue assay, 72 h after transfection with siRNA anti-survivin (siSURV) or with siMUT and/or cell incubation with the chemotherapeutical drugs etoposide (ETO) and Bliss interaction index (D) determined for the combined effects on cell viability of survivin silencing plus treatment with each drug. Cells were transfected, for 4 h, with (14Ser)2N5/siRNA/HL complexes and, after an additional period of 20 h, cells were incubated with 1.5 μM ETO (C) for 48 h. Results, representative of at least three independent experiments, are expressed as a percentage of the nontreated control cells. Combined treatment (dotted bar) was compared with the single drug treatment (gray bar) (**p < 0.01, ***p < 0.001) and the Bliss interaction index of each combined treatment was compared with the theoretical value expected for an additive effect (1.0) (#p < 0.05, ns, non-significant).

    Eur J Pharm Biopharm, 2016, 104:7-19.. Etoposide purchased from Selleck.

    Cellular biomarker responses in HT29 cells exposed to various cytotoxic chemotherapeutic agents in combination with the Chk1 inhibitor V158411. HT29 cells were exposed to the combination GI80 of gemcitabine (0.2 uM), camptothecin (0.44 uM), cisplatin (68 uM), oxaliplatin (131 uM), doxorubicin (1.2 uM) or etoposide (59 uM) for 18 hours followed by DMSO (-) or 400 nM V158411 (+) for a further 24 hours. Protein expression was characterized by immunoblotting.

    BMC Cancer 2014 14, 483. Etoposide purchased from Selleck.

  • (c) and (d) Effects of fractions C4 and C5 on topoisomerase II activity. Topoisomerase II activity was measured by plasmid DNA cleavage assay. DNA bands were visualized using UV light and the intensity of linear DNA band in each lane was measured using imageJ software. Lane 1: plasmid PBR322DNA. Lane 2: control, topoisomerase II + plasmid PBR322DNA. Lanes 3, 4, and 5: 40, 20, and 10 μg/mL fraction C4 + plasmid PBR322DNA, respectively. Lanes 6, 7, and 8: 40, 20, and 10 μg/mL fraction C5 + plasmid PBR322DNA, respectively. Lane 9: 100 μM etoposide + plasmid PBR322DNA. The data in different groups were expressed as the mean ± SD from 3 experiments. Statistical difference between groups was assessed by t-test using SPSS 20.0. ∗∗P < 0.01 versus the control group.

    Evid Based Complement Alternat Med, 2017, 2017:1456786. Etoposide purchased from Selleck.

    Effects of etoposide on the radiosensitivities of cholangiocarcinoma cell lines. The cell survival curves of (A) KKU-M055 and (B) KKU-M214 cells were obtained from clonogenic survival assays. The cells were treated with X-ray irradiation or etoposide (0.025 or 0.05 µg/ml) alone or pretreated with etoposide for 24 h prior to X-ray irradiation. Survival fractions were determined at day 10 following X-ray irradiation. The dose-response curves depict the mean ± standard deviation of survival fractions of three independent experiments. IR, irradiation.

    Oncol Lett, 2018, 15(3):3895-3903. Etoposide purchased from Selleck.

製品安全説明書

Topoisomerase阻害剤の選択性比較

生物活性

製品説明 Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.
ターゲット
Topo II [2]
(Cell-free assay)
体外試験

Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA, which induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. [1] Etoposide inhibits the growth of murine angiosarcoma cell line (ISOS-1) in a 5 days-period with IC50 of 0.25 μg/mL. Cell growth of normal murine microvascular endothelial cells (mECs) is less sensitive to Etoposide with IC50 of 10 μg/mL). [2] Etoposide treated for 6 hr inhibits colonies of tetraploid variant of the human leukemic lymphoblast line CCRF-CEM with IC50 of 0.6 μM. [3] Etoposide treated for 2 hr inhibits growth of human pancreatic cancer cell line Y1, Y3, Y5, Y19, YM. YS, and YT with IC50s of 300 μg/mL, 300 μg/mL, 300 μg/mL, 91 μg/mL, 0.68 μg/mL, 300 μg/mL, 300 μg/mL, and 260 μg/mL, respectively. [4] Etoposide exposed for 1 hr inhibits growth of human glioma cell lines CL5, G142, G152, G111, and G5 with IC50 of 8, 9, 9.8, 10, and 15.8 μg/mL respectively for 12 days. Under same condition, the IC90 value is attained in cell lines CL5, G152, G142, and G111 at 26, 27, 32, and 33 μg/mL. Etoposide inhibition of topoisomerase II is homogeneous for each cell. The average inhibition rates are 15%, 21.8%, 31.8%, 41.5%, and 49.5% for 1, 2, 4, 8, and 16 μg Etoposide, respectively. [5]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly NGHaOpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPETWM2OD1yLkGy5qCKyrIkgJmwMlAyKM7:TR?= M4DXU|I2QTZyMkiy
KellyCis83 NGXsO|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTBwMUdihKnDueLCiUCuNFIh|ryP NWPmO2tqOjV7NkCyPFI>
SK-N-AS MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLBUI1KSzVyPUCuNlTjiIoEsfMAjVAvODNizszN NVfSW493OjV7NkCyPFI>
SK-N-ASCis24 NEi3WHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{G4dWlEPTB;MD61O-KBkcLz4pEJNE4yOSEQvF2= NYn4[3NuOjV7NkCyPFI>
U87 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXWwMVUxKM7:TR?= NFPaTJI1QCCq M{jNZ4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTD3bIlkcCClYX6gZoUh\W6qYX7j[YQh[nlic3nsbYJqdmmw NU\XOY9KOjV5NUCyO|M>
HCT116 NFX4emJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrvNE42NTJwNTFOwG0> Mly5OFjDqGkEoB?= NHnyNZpKSzVyPUGuO|PDqMLzwrCwMlIyyqEQvF2= NVHGeYI5OjV5NE[3OlM>
HT-29 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHRNE42NTJwNTFOwG0> NXexRWMxPDkEoHlCpC=> MnPOTWM2OD15LkNCpOKyyqBzLkC0xsDPxE1? MmjjNlU4PDZ5NkO=
Caco2 MmrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoThNE42NTJwNTFOwG0> NVPjO3lXPDkEoHlCpC=> M13m[GlEPTB;Nz6yOuKhyrIEoEGuOljDqM7:TR?= M2\BfVI2PzR4N{[z
COLO 205 NEf1cFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3z2VFAvPS1{LkWg{txO M2TMUlQ5yqCqwrC= NX\W[3pLUUN3ME2xMlYyyqEEsdMgNE4xOsLizszN MlTBNlU4PDZ5NkO=
SW480 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXmW4Q{OC53LUKuOUDPxE1? NUTtcIQ4PDkEoHlCpC=> NULQfYVjUUN3ME20MlkzyqEEsdMgNE4{O8LizszN M37OZVI2PzR4N{[z
HEK293T NYnFWFdbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2C2VlEuPSEQvF2= NULLVZczPDkEoHlCpC=> M4riPWlEPTB;Mj60NuKhyrIEoECuNFXDqM7:TR?= MnO3NlU4PDZ5NkO=
Hep3B  NEO0dJhHfW6ldHnvckBCe3OjeR?= MWmxNEDPxE1? MmrpOFjDqGkEoB?= MY\y[YR2[2W|IITo[UBmdmijbnPpcoch\W[oZXP0JI9nKEKPUD22 MX2yOVY{OzV4NB?=
Hep3B  NWDib483TnWwY4Tpc44hSXO|YYm= NYHBdpdQOC5zLUGwJO69VQ>? NGPHTmwzPCCq NY\5RVlbe3WycILld5NmeyC2aHWg[ZhxemW|c3nvckBw\iCqZYDjbYRqdiCvUl7B MlzPNlU3OzN3NkS=
HEK293 NELCOJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTdwMUVCpOKyyqByLkO2xsDPxE1? MnvSNlU3ODNzMkK=
DU145 M3fjXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHaTWM2OD1{LkK4xsDDucLiMD6wOOKh|ryP M{TORlI2PjB|MUKy
HCT15 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfRWphKSzVyPUCuPFHDqMLzwrCwMlAyyqEQvF2= MUKyOVYxOzF{Mh?=
T47D MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmX3TWM2OD1|LkG4xsDDucLiMD6xNeKh|ryP MoKzNlU3ODNzMkK=
SMMC-7721 NFftfFFHfW6ldHnvckBCe3OjeR?= MU[0NEDPxE1? NFzYN3Y1QCCq NXj4dW9DTE2VTx?= M2XxNolv\HWlZYOg{tNJOkG[IH\vZ4kh\m:{bXH0bY9v MWqyOVU1PDN4MR?=
MDA-MB-231 NH7G[G5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTWd|V[PzMEoHi= M1f4VGlEPTB;MkGuNuKhyrIEoESuNuKh|ryP MmDrNlU1QDZ{MUm=
MCF-7 NXy2cIkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfW[ng4OsLiaB?= MlTkTWM2OD1zMD65xsDDucLiMj6xxsDPxE1? MmDSNlU1QDZ{MUm=
Jurkat MkHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnjUHk4OsLiaB?= M4LQfmlEPTB;MT6yxsDDucLiMT61xsDPxE1? NF7NSoozPTR6NkKxPS=>
HeLa NHS4[oNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLOT5I4OsLiaB?= Mk\ITWM2OD1|LkpCpOKyyqB{LkRCpO69VQ>? NFK4RZMzPTR6NkKxPS=>
MCF7  MnjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\vPYp3PS1zMECg{txO M3;xO|ch\A>? NXzZWpVbcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M165dlI2PDd{NkG5
K562 NXPDeGhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3[3c|czyqCq MkDuTWM2OD1yLkK5xsDPxE1? NHPmco4zPTJ6Mk[1Ny=>
K/VP.5 NIi5NXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3m[Io4OsLiaB?= Ml;GTWM2OD12LkpCpO69VQ>? M1uyOlI2Ojh{NkWz
SH-EP  Mli2SpVv[3Srb36gRZN{[Xl? MlfsNlDDqM7:Zz;tcC=> NVPnXppPOjUEoHi= M3rCU4lv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBmdmSxZ3Xuc5V{KESHUGC= NF[zV5MzPTJ4MUm4NS=>
SCC25 NEfzRW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LTclI1yqCq M1Sz[mlEPTB;NEOuN:KhyrIEoEGuNVLDqM7:TR?= NHjufWEzPTJ{MEeyPS=>
CAL27 M3W1UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjXcWJkOjUEoHi= NGnEdWdKSzVyPUWyMlHDqMLzwrCxMlA6yqEQvF2= NIHic3EzPTJ{MEeyPS=>
FaDu MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljRNlTDqGh? M1;YO2lEPTB;MkWuPFnDqMLzwrCxMlE{yqEQvF2= MnXiNlUzOjB5Mkm=
SCC25 NFT3V5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLk[oM1QMLiaB?= NXLBW|FEUUN3ME2yNE45PsLiwsJCpFEvODgEoN88US=> NXfzbFZKOjV{MkC3Nlk>
CAL27 MmnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXzOFjDqGh? MWnJR|UxRTF6LkK0xsDDucLiMT6xOeKh|ryP MkLYNlUzOjB5Mkm=
FaDu MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHTSmM1QMLiaB?= M3\mTGlEPTB;Nj60N:KhyrIEoEGuNVPDqM7:TR?= M165XFI2OjJyN{K5
SCC25 NVyyTZBpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXqO|LDqGh? NEXRPFhKSzVyPUiuOFHDqMLzwrCxMlEyyqEQvF2= NG\qZYIzPTJ{MEeyPS=>
CAL27 MnXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXndW84OsLiaB?= M2WxPWlEPTB;ND6yO:KhyrIEoEGuNVTDqM7:TR?= NYPkb5UyOjV{MkC3Nlk>
FaDu NEfmWY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXS3NuKhcA>? NULxd3FyUUN3ME21MlAzyqEEsdMgNU4yPcLizszN MV:yOVIzODd{OR?=
MCF-7 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4D3[lQ5yqCqwrC= NWn0SpBNTE2VTx?= NHPwUJVKSzVyPUeuNuKhyrIEoECuPOKh|ryP M3v3XFI2OjF4M{e4
T-47D NVPJZ5loT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13DU|Q5yqCqwrC= NYOwXoR4TE2VTx?= NY\BdHdkUUN3ME23MlfDqMLzwrCwMlfDqM7:TR?= M1jh[lI2OjF4M{e4
MDA-MB-231 NUi5[ZJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7SWFA1QMLiaNMg NXztZlFlTE2VTx?= MnrmTWM2OD1zMj64xsDDucLiMT6wxsDPxE1? NWX2eVBGOjV{MU[zO|g>
DU145 NI\tS|BCeG:ydH;zbZMhSXO|YYm= NHHqXm4yOC1zMECg{txO NVTyUY1vQCCq MmfjSG1UVw>? NX65[FhYcW6mdXPld{Bk\WyuIHTlZZRpKHOrZ37p[olk[W62bImgbY4h[SC4ZYL5JIxwfyClb37j[Y51emG2aX;u MXKyOVE1QTZ6MR?=
DU145 stem-like Mn73RZBweHSxc3nzJGF{e2G7 M3zyNlExNTFyMDFOwG0> M4S5OFghcA>? NX7MeWYxTE2VTx?= M{\ifolv\HWlZYOgZ4VtdCCmZXH0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MkXhNlUyPDl4OEG=
DU145 M3HtOmZ2dmO2aX;uJGF{e2G7 NWfCU3R3OTBvMUCwJO69VQ>? MUeyJIg> NGnRdG1FVVOR NYPEVmtocW6lcnXhd4V{KHSqZTDwR2hMOSCneIDy[ZN{cW:wIHHu[EBl\WO{ZXHz[ZMhfGinIIDDTGsyKGW6cILld5Nqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? Mo\lNlUyPDl4OEG=
DU145 stem-like NGnRXJRHfW6ldHnvckBCe3OjeR?= NHLLe3oyOC1zMECg{txO MUOyJIg> NFzmdXZFVVOR M4q5O4lv[3KnYYPld{B1cGVicFPIT|Eh\XiycnXzd4lwdiCjbnSg[IVkemWjc3XzJJRp\SCyQ1jLNUBmgHC{ZYPzbY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MmHFNlUyPDl4OEG=
UW228-3 NI\mRmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoP3NE4xOS1|MECg{txO MkL1OFghcA>? MX;EUXNQ MkPCTWM2OD1yLkm5xsDPxE1? MXeyOVEyQTF6NR?=
NSCs NVHXeVBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHEdYZoOC5yMT2zNFAh|ryP Ml;COFghcA>? MUTEUXNQ NHLLV5ZKSzVyPUCuN{0{yqEQvF2= NWPuRlJtOjVzMUmxPFU>
MKL-1  NXrrfHU5TnWwY4Tpc44hSXO|YYm= MnrjNVAuOTByMDDuUS=> NFrqdoI1KGR? MnW2bY5lfWOnczD0bIUhcW6mdXP0bY9vKG:oIF3IR{1KKGW6cILld5Nqd25? NUTuWmQ1OjVzMU[3OVQ>
MCF7 EV M3rqV2Z2dmO2aX;uJGF{e2G7 NUT2NlZTOTBvMUCwJO69VQ>? Mn\6NwKBkWh? NFfNS2dqdmS3Y3XzJJBzd2S3Y4Tpc44hd2cEoN8zTFJCYA>? NVnBNlNFOjVyOEiyNFM>
MCF 7BMI1 NUTrZmhRTnWwY4Tpc44hSXO|YYm= MWixNE0yODBizszN MUOy5qCKcA>? NGrEU5BqdmS3Y3XzJJBzd2S3Y4Tpc44hd2cEoN8zTFJCYA>? NFu2XZMzPTB6OEKwNy=>
MCF7 EV NGnBepZHfW6ldHnvckBCe3OjeR?= NVy1e3gzOTBvMUCwJO69VQ>? MlXlNwKBkWh? M{fJRWVVV1BiaX7keYNmeyCDVF2gZYN1cX[jdHnvci=> MWqyOVA5QDJyMx?=
MCF7 BMI1 NEjzN4pHfW6ldHnvckBCe3OjeR?= NF24O44yOC1zMECg{txO NXzkcHV{OuLCiXi= Mk[5SXRQWCCrbnT1Z4V{KEGWTTDhZ5RqfmG2aX;u MX2yOVA5QDJyMx?=
HepG2 Mn2wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnZVZFSTE2VT9Mg MlzITWM2OD1|MD6xOuKhyrIEoECuOVDDqM7:TR?= M{PTS|I2ODd6M{Gx
MOLT-3 NUn6NZhnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPiSG1UV8Li NUXrfWY5UUN3ME2wMlA2OcLiwsJCpFAvODB{wrFOwG0> NXK2VG1SOjVyN{izNVE>
HT1080 MofRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYSxMVExOCEQvF2= MVm0M|I1NzR6IHi= MXPEUXNQyqB? NYDz[2lPcW6mdXPld{Bk\WyuIHTlZZRpKHOrZ37p[olk[W62bImgbY4h[SC4ZYL5JIxwfyClb37j[Y51emG2aX;u NXqwXFJzOjVyN{iwOlQ>
HT1080 MUfGeY5kfGmxbjDBd5NigQ>? Ml3mNE4xODBzLUGwNEDPxE1? NIXXWmMyNTJ2IHi= MofBSG1UV8Li NEHQSmdqdmS3Y3XzJJAueDV|KIPldlE2MSCrbjDic5RpKHSrbXWtJIFv\CClb37j[Y51emG2aX;uMYRmeGWwZHXueEBu[W6wZYK= NF;Sd|QzPTB5OEC2OC=>
HT1080 M4PwVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;MTYtHOC5yMECxMVExOCEQvF2= NUXFTpRIOjRiaB?= NIW3XINFVVORwrC= NVPURZQ6[2G3c3XzJIFvKGmwY4LlZZNmKGmwIITo[UBvfW2kZYKgc4Yh[2WubIOgbY4hTzJxTTyge4hqdGViZHXjdoVie2mwZzDTJIFv\CCJMTDwbIF{\SClZXzsdy=> NUXxOG1wOjVyN{iwOlQ>
HD-MY-Z NUnXRYlET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1i0cVI1NzR6L{eyJIg> M3zTO2lEPTExvK6xNFAh|ryP M{HuSFI2ODR6MkO2
DOHH-2 MoW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLDV4wzPCCq M3PncmlEPTExvK6xNFAh|ryP NX3iSpZEOjVyNEiyN|Y>
DOHH-2 MnLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1G1T|Q5KGh? MX3JR|UxRTF7LkpCpO69VQ>? NYCzd2luOjVyNEiyN|Y>
DOHH-2 MkfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jKW|czKGh? MoXDTWM2OD13wrFOwG0> NGDWWWozPTB2OEKzOi=>
REH M4Xz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYSyOEBp NGPkPVFKSzVyPUCuNFI4yqEQvF2= MWSyOVA1QDJ|Nh?=
REH NV;6eoN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4f0d|Q5KGh? MkPnTWM2OD1yLkCxOOKh|ryP NULJT|lWOjVyNEiyN|Y>
REH NVPXd|Z5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrTbIRxPzJiaB?= NUnNcVFpUUN3ME2wMlAyPcLizszN NVSwbo9IOjVyNEiyN|Y>
HH NWX3dFlVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIW4dnkzPCCq NV;qU5JPUUN3ME2xNFQvP8LizszN M4H6SlI2ODR6MkO2
HH NEPTXXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrBUJBYPDhiaB?= NXzFdmRWUUN3ME20PE43yqEQvF2= M2e0RlI2ODR6MkO2
HH MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnNUo05PzJiaB?= M3rocGlEPTB;MUSuO:Kh|ryP Ml7SNlUxPDh{M{[=
HuT-78 NXnH[2YxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITGOpUzPCCq NGjqZnJKSzVyPUmuN:Kh|ryP NF3wTWUzPTB2OEKzOi=>
HuT-78 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXyOFghcA>? NX7qPJA3UUN3ME20MlPDqM7:TR?= M2fveFI2ODR6MkO2
HuT-78 NHvLfmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnWV4NEPzJiaB?= NV6yS5hlUUN3ME20MlLDqM7:TR?= MVGyOVA1QDJ|Nh?=
OPM-2 NVPa[pF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4GxO|I1KGh? MoHoTWM2OD1{ND6xxsDPxE1? MVqyOVA1QDJ|Nh?=
OPM-2 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUK0PEBp NWnYXYt3UUN3ME20xsDPxE1? NWfiNnJpOjVyNEiyN|Y>
OPM-2 NFKxTG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV:3NkBp NWX5Spc5UUN3ME2xMlPDqM7:TR?= M4TITFI2ODR6MkO2
RPMI-8226 M1nyZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV[yOEBp M3LUUWlEPTB;MUC2MlbDqM7:TR?= MX:yOVA1QDJ|Nh?=
RPMI-8226 M1HXSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rtW|Q5KGh? M3zjfWlEPTB;OUGuNeKh|ryP M3Swc|I2ODR6MkO2
RPMI-8226 M1W3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXO0OVNKPzJiaB?= MnfSTWM2OD1zND65xsDPxE1? NEftdYMzPTB2OEKzOi=>
U-266 MnO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPUVmFWOjRiaB?= M2rwT2lEPTB;OE[uNuKh|ryP MWGyOVA1QDJ|Nh?=
U-266 NVLXVXRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3mfJY1QCCq M2\aSWlEPTB;NkiuOOKh|ryP MlnUNlUxPDh{M{[=
U-266 M3rjZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUm3NkBp MXTJR|UxRTJ5LkVCpO69VQ>? M2PwNFI2ODR6MkO2
Kelly NIjFPIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfxeIMxNTFyIN88US=> MXK3NuKhcA>? NVviXmd3UUN3ME2xMlUyQMLizszN MXqyOVAxQDlyMB?=
SH-SY5Y  MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fhflAuOTBizszN M3GzSVczyqCq NWTQb5h[UUN3ME2wMlc2PMLizszNxsA> NILoPGgzPTByOEmwNC=>
SK-N-AS NH;KfphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn64NE0yOCEQvF2= M33Z[|czyqCq MULJR|UxRTFwN{GyxsDPxE4EoB?= M2\TS|I2ODB6OUCw
SK-N-DZ NUDKVHFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TRb|AuOTBizszN NVL6UIZlPzMEoHi= MXrJR|UxRTVwNEi1xsDPxE1? M2Xad|I2ODB6OUCw
HepG2 MoS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mof6OFjDqGh? M3rGdWROW00EoB?= NEXVN5NKSzVyPUGzMlY2yqEEsdMgNE46OsLizszN NXvUcXdGOjR7OU[xN|Y>
A549 NGXVbGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;RS4g1QMLiaB?= M13zUmROW00EoB?= NIezc41KSzVyPUK0NU46yqEEsdMgN|EvOjQEoN88US=> NWD0Uol5OjR7OU[xN|Y>
MCF7 NV;COJExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVO0POKhcA>? NFfrZXZFVVORwrC= MXLJR|UxRThzLkC5xsDDucLiMUSuNlHDqM7:TR?= NU\tWIY3OjR7OU[xN|Y>
HL-60  MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvD[IY4OsLiaB?= MUfJR|UxRTBwMUNihKXPxE1? MVOyOFk6OzBzNB?=
HL-60[R] MoLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFznSZA4OsLiaB?= NGjmVJdKSzVyPUOuNVLjiIYQvF2= M{jJW|I1QTl|MEG0
MIAPACA MmLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zVeWdKPTB;MT6zJOKyKDBwMEOg{txO MXqyOFk2Ozh{MR?=
MCF-7 MmrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfHTVUxRTBwMkWgxtEhOC5zIN88US=> NILFfoszPDl3M{iyNS=>
HeLa M3fn[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\IS2k2OD1yLk[0JOKyKDBwNDFOwG0> NIXxWGEzPDl3M{iyNS=>
MO59K  NVmwVo5TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\KWIk4KGR? NVvOem9ZUUN3ME2wMlE46oDHzszN NGjk[Y4zPDl3M{W2NS=>
MO59J M2nlbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVu3JIQ> MorqTWM2OD1yLkJihKXPxE1? M4TSeVI1QTV|NU[x
ME 180 M{nae2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIK2eWM1QMLiaNMg MV\JR|UxRThwOdMgxtHDqDBwM,MAie69VQ>? M3joblI1QTV|MEK3
MCF-7 NFHZPGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1P1elQ5yqCqwrC= MYfJR|UxRTJ|LkmgxtEhOC5|4pEF{txO M{[wVlI1QTV|MEK3
HeLa NILLd3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY[0POKhcMLi MX\JR|UxRTRwN{GgxtEhOS524pEF{txO Mn3lNlQ6PTNyMke=
MDA-MB-453 NXjBO4VVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX[xcXdLPDkEoHlCpC=> M3viO2lEPTB;MUKuOUDDuSByLki15qCG|ryP MWSyOFk2OzB{Nx?=
MDA-MB-231 M{PoNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWW0POKhcMLi NUfjVYZXUUN3ME2yOE4zOiEEsTCyMlk16oDHzszN NXXnPFNYOjR7NUOwNlc>
PC-3 NFHYTolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTZVHRqPDkEoHlCpC=> NY\OSHVbUUN3ME2xOE41KMLzIEOuNlPjiIYQvF2= MkLYNlQ6PTNyMke=
HT-29 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3NXVV4PDkEoHlCpC=> M{nnfWlEPTB;MkGuOFUhyrFiMz64O-KBjc7:TR?= MmHKNlQ6PTNyMke=
BGC-823 NEfmOXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXvOFjDqGkEoB?= MXHJR|UxRTR|Lke0JOKyKDVwMURihKXPxE1? Mnr3NlQ4QTN6N{e=
HeLa MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\kfo01QMLiaNMg M3H3[2lEPTB;MkC5MlkxKMLzIEGzMlQzKOLChd88US=> MlztNlQ4QTN6N{e=
A549 MmC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYD5fI5jPDkEoHlCpC=> M{\Db2lEPTB;MUO5MlU1KMLzIEeuNFXjiIYQvF2= MXyyOFc6Ozh5Nx?=
HK-2 MmDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfoUHdGPDkEoHlCpC=> MVfJR|UxRTlwMUegxtEhOS53OPMAie69VQ>? NV3FTYdsOjR5OUO4O|c>

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 Etoposide administrated as a single agent is found to been ineffective in many xenografts growth, such as Heterotransplanted Hepatoblastoma NMHB1, and NMHB 2, [6] human neuroblastoma xenograft, [7] and human gastrointestinal cancer xenograft, [8] while the dose of 10 mg/kg i.p. Etoposide inhibits murine angiosarcoma cell ISOS-1 tumors in 36% of controls. [2] Etoposide induces tumor immunity in Lewis lung cancer. A single administration of 50 mg/kg Etoposide i.p., induces a 60% survival of C57B1/6 mice injected with Lewis lung cancer cell (3LL) over 60 days. About 40% of these surviving mice reject a subsequent challenge with 3LL, while none of control mice survive beyond 30 days. 3LL cells which have survived an 90% lethal concentration of Etoposide in vitro kill 75% of recipient mice, but 60% surviving mice reject challenge with 3LL. Splenocytes harvested from tumor rejecting mice protect naive mice injected with 3LL. [9]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[5]
+ 展開

Topoisomerase II activity assay:

Nuclear extracts are prepared, and nuclei are isolated. The activity of topoisomerase II is calculated from the percentage of decatenation obtained. Tritiated kinoplast DNA (KDNA 0.22 μg) is used as a substrate. Etoposide and topoisomerase II are incubated for 30 min at 37 ℃ and are stopped with 1% sodium dodecyl sulfate (SDS) and proteinase K (100 μg/mL). The percentages of decatenation and inhibition of topoisomerase II by Etoposide are obtained.
細胞試験: [5]
+ 展開
  • 細胞株: Human glioma cell lines CL5
  • 濃度: 80 μg/mL
  • 反応時間: 1 hour
  • 実験の流れ: After the Etoposide treatment, cells are removed from the dish with phosphate-buffered saline (PBS) containing 0.03% trypsin and 0.27 mM ethylenediaminetetraacetic acid (EDTA) and are diluted into culture dishes in appropriate numbers to yield between 20 and 200 colonies. After 12 days, cultures are fixed with methanol-acetic acid, stained with crystal violet, and scored for colonies containing more than 50 cells. The standard errors are typically less than 15% of the mean value unless otherwise stated.
    (参考用のみ)
動物試験:[2]
+ 展開
  • 動物モデル: Murine angiosarcoma xenografts ISOS-1
  • 製剤: Saline
  • 投薬量: 10 mg/kg
  • 投与方法: i.p. every day for 5 days from day 7
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 100 mg/mL (169.9 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
5% DMSO+30% PEG 300+H2O
混合させたのち直ちに使用することを推奨します。
15mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 588.56
化学式

C29H32O13

CAS No. 33419-42-0
保管
in solvent
別名 VP-16, VP-16213

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03583424 Recruiting Hematopoietic Cell Transplantation Recipient|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma|Refractory Marginal Zone Lymphoma|Refractory Non-Hodgkin Lymphoma|Refractory Transformed Indolent Non-Hodgkin Lymphoma Ohio State University Comprehensive Cancer Center|National Cancer Institute (NCI) July 9 2018 Phase 1|Phase 2
NCT03126916 Recruiting Childhood Ganglioneuroblastoma|Childhood Neuroblastoma|INRG Stage L2|INRG Stage M|INRG Stage MS|NMYC Gene Amplification|Recurrent Neuroblastoma Children''s Oncology Group|National Cancer Institute (NCI) May 9 2018 Phase 3
NCT03519971 Recruiting Non-Small Cell Lung Cancer AstraZeneca April 9 2018 Phase 3
NCT03407144 Recruiting Hodgkin Lymphoma Merck Sharp & Dohme Corp. April 9 2018 Phase 2
NCT03136146 Recruiting Hematopoietic/Lymphoid Cancer|Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma|Burkitt Leukemia/Lymphoma M.D. Anderson Cancer Center August 9 2017 Phase 2
NCT03432598 Recruiting Locally Advanced or Metastatic Lung Cancer BeiGene August 9 2017 Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    Regarding the Etoposide S1225, do you have any data of the inhibition sepcificity of this product? It will inhibit other enzymes other than TOP2A?

  • 回答:

    According to the available published data, the inhibition of Etoposide is specific to TOP2A. But there're also two papers showing that Etoposide could inhibit the p34cdc2 Kinase Activity: 1. http://cancerres.aacrjournals.org/content/52/7/1817.short ; 2. http://cancerres.aacrjournals.org/content/50/12/3761.short.

Topoisomeraseシグナル伝達経路

相関Topoisomerase製品

Tags: Etoposideを買う | Etoposide ic50 | Etoposide供給者 | Etoposideを購入する | Etoposide費用 | Etoposide生産者 | オーダーEtoposide | Etoposide化学構造 | Etoposide分子量 | Etoposide代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID